- Home
- RAPP vs AQST Comparison
RAPP vs AQST Comparison
Compare RAPP & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAPP
- AQST
- Stock Information
- Founded
- RAPP 2022
- AQST 2004
- Country
- RAPP United States
- AQST United States
- Employees
- RAPP N/A
- AQST N/A
- Industry
- RAPP
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- RAPP
- AQST Health Care
- Exchange
- RAPP Nasdaq
- AQST Nasdaq
- Market Cap
- RAPP 439.4M
- AQST 390.4M
- IPO Year
- RAPP 2024
- AQST 2018
- Fundamental
- Price
- RAPP $14.71
- AQST $4.11
- Analyst Decision
- RAPP Strong Buy
- AQST Strong Buy
- Analyst Count
- RAPP 3
- AQST 6
- Target Price
- RAPP $33.67
- AQST $10.67
- AVG Volume (30 Days)
- RAPP 162.2K
- AQST 1.2M
- Earning Date
- RAPP 08-07-2025
- AQST 08-11-2025
- Dividend Yield
- RAPP N/A
- AQST N/A
- EPS Growth
- RAPP N/A
- AQST N/A
- EPS
- RAPP N/A
- AQST N/A
- Revenue
- RAPP N/A
- AQST $44,132,000.00
- Revenue This Year
- RAPP N/A
- AQST N/A
- Revenue Next Year
- RAPP N/A
- AQST $51.62
- P/E Ratio
- RAPP N/A
- AQST N/A
- Revenue Growth
- RAPP N/A
- AQST N/A
- 52 Week Low
- RAPP $6.43
- AQST $2.12
- 52 Week High
- RAPP $29.74
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- RAPP N/A
- AQST 58.49
- Support Level
- RAPP N/A
- AQST $3.69
- Resistance Level
- RAPP N/A
- AQST $4.24
- Average True Range (ATR)
- RAPP 0.00
- AQST 0.24
- MACD
- RAPP 0.00
- AQST -0.01
- Stochastic Oscillator
- RAPP 0.00
- AQST 72.41
About RAPP Rapport Therapeutics Inc. Common Stock
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.